Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd. (Nasdaq: PRFX) generates news across two main areas: specialty pharmaceutical development for post-surgical pain and ophthalmology, and AI-driven solar and energy analytics through its DeepSolar platform. Company updates often highlight progress in extended-release drug-delivery technologies and in advanced digital tools for managing solar assets.
On the pharmaceutical side, news items cover developments in PRF-110, PainReform’s oil-based ropivacaine formulation for localized post-operative analgesia, and the OcuRing™-K program acquired through its majority investment in LayerBio. Releases describe preclinical and clinical milestones for OcuRing-K, including Phase I safety data in cataract surgery patients and R&D assessments showing that the sustained-release matrix can incorporate multiple drug entities such as corticosteroids and NSAIDs. These updates provide insight into how the company is pursuing dropless, sustained-release approaches to post-cataract pain and inflammation management.
In parallel, DeepSolar-related news focuses on AI-based solar analytics and energy optimization. Coverage includes the development of DeepSolar Predict, an AI forecasting module for photovoltaic systems advanced within the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and progress on an automated reporting engine that consolidates operational data into tailored performance reports. PainReform has also reported on pilot and commercial engagements for DeepSolar, such as a 92MW project with Econergy Renewable Energy.
Investors and observers can use this news feed to follow regulatory and clinical steps for PainReform’s pharmaceutical candidates, as well as product launches, technology collaborations, and commercial milestones in its DeepSolar business. Regular updates provide context on how the company advances its dual focus on non-opiate pain management and renewable-energy analytics.
PainReform (Nasdaq: PRFX) reported that preclinical rabbit studies and a Phase I clinical study of the OcuRing™-K drop-less sustained-release ocular delivery platform showed a favorable safety profile on Jan 12, 2026. The Phase I trial in cataract surgery patients recorded no treatment-related adverse events, no serious adverse events, and proper device positioning in all treated eyes. Preclinical results showed no ocular tissue abnormalities and no meaningful differences versus control. PainReform and majority-owned LayerBio are advancing IND-enabling activities to support next-phase clinical evaluation in the United States.
PainReform (Nasdaq: PRFX) announced on January 5, 2026 that its DeepSolar unit launched Smart TDD, a lifecycle-wide solar Technical Due Diligence service targeting the global solar asset M&A market. Smart TDD combines 100% component and operational-history coverage, AI-driven analytics with physics-based modeling, expert engineering review, prioritized findings by financial impact, and preliminary results delivered within days. The release cites a large addressable market—$500 billion invested in 2024 and more than $60 billion of solar assets traded annually—and positions Smart TDD for use at commissioning, warranty expiry, underperformance remediation, and asset acquisitions.
BladeRanger (TASE: BLRN) will showcase its drone-based inspection, maintenance and AI-driven analytics platforms at Abu Dhabi Sustainability Week on Dec. 30, 2025.
The company will highlight its Solar Drone platform and its cooperation with PainReform (NASDAQ: PRFX) DeepSolar for monitoring, analytics and operational optimization of utility-scale solar and complex energy infrastructure. BladeRanger said it held strategic meetings in Dubai with regional energy groups and views ADSW participation as a step to expand presence and strengthen ties with UAE stakeholders amid the region’s major investments in hyperscale data centers and energy systems.
PainReform (Nasdaq: PRFX) announced on December 10, 2025 that its pharmaceutical division completed an R&D assessment of LayerBio’s drop-less, sustained-release ocular platform.
The assessment confirmed the platform’s polymer matrix can incorporate multiple drug entities, specifically corticosteroids and NSAIDs, supporting technical feasibility for multi-drug loading. LayerBio’s pre-fabricated OcuRing is placed intraocularly during cataract surgery to provide sustained, targeted delivery at a fraction of total drug amounts used by eye-drop regimens. The company said this approach may reduce or eliminate reliance on postoperative medicated eye drops, improve compliance among elderly cataract patients, and simplify postoperative care.
PainReform (Nasdaq: PRFX) commenced development of OcuRing-K, LayerBio’s intraoperatively administered, erodible sustained‑release ocular device, and is advancing toward a Phase II clinical trial for post‑cataract pain and inflammation.
OcuRing‑K delivers controlled ketorolac release to target tissues, aims to replace multi‑week eye‑drop regimens, and showed pain and inflammation reductions in preclinical studies and a Phase I evaluation with lower total drug exposure. The program targets the large cataract surgery market (~4.5M US surgeries; ~$9B global annual procedure volume) and may expand to additional ophthalmic indications pending further clinical progress and regulatory approval.
PainReform (Nasdaq: PRFX) said DeepSolar has advanced development of an AI-driven automated reporting engine for solar-asset analysis.
The engine is designed to consolidate SCADA, monitoring, weather and market data, reduce manual aggregation, and deliver customized, insight-rich performance reports within minutes. Users can set analysis depth, visualization style, and reporting frequency to support operations, management and investor reporting.
PainReform (Nasdaq: PRFX) said its DeepSolar unit was featured in a Watchlist Interview after joining the NVIDIA Connect program, spotlighting development of DeepSolar Predict, an AI forecasting module for photovoltaic (PV) assets.
The system combines advanced weather modeling and AI to raise forecast resolution, help solar-asset managers reduce imbalance penalties, optimize energy-sale timing, and support pilot project progress toward commercial deployment.
PainReform (Nasdaq: PRFX) reported significant developments for H1 2025, marking a strategic shift into both pharmaceuticals and renewable energy. The company completed a majority investment in LayerBio, acquiring OcuRing™-K, a dropless cataract therapy targeting a $9B global market. Their pharmaceutical pipeline includes ongoing R&D for PRF-110, which showed early positive efficacy in postoperative pain.
The company's DeepSolar division achieved notable milestones, including the completion of MyDeepSolar app, acceptance into NVIDIA Connect Program, and conversion of a 92MW pilot with Econergy into their first commercial agreement. Financially, PainReform reduced its net loss to $2.3M from $12.8M year-over-year, maintaining $3.5M in cash and $1.5M in positive working capital.
PainReform (Nasdaq: PRFX) announced that its solar energy business unit, DeepSolar, has been accepted into the prestigious NVIDIA Connect Program. This collaboration will advance DeepSolar Predict, the company's AI-driven solar forecasting solution for photovoltaic systems.
The technology is expected to improve weather forecast accuracy by up to 50% and reduce operational and maintenance costs by up to 30%. DeepSolar Predict aims to help solar asset owners optimize energy sale timing, reduce forecast penalties, and strengthen grid stability through more predictable supply.
The NVIDIA Connect Program provides DeepSolar with access to AI frameworks, development tools, and engineering support, positioning the company to become a key player in performance-driven solar asset management.
PainReform (Nasdaq: PRFX) has completed a strategic investment in LayerBio, acquiring a majority equity stake to enter the $9 billion global cataract surgery market. The company's focus is on LayerBio's OcuRing™-K technology, a breakthrough non-opiate, non-steroidal postoperative drug delivery system.
OcuRing™-K is a bioerodible intraocular ring designed to deliver Ketoralac during cataract procedures, offering a "dropless" alternative to traditional postoperative eye drop regimens. The technology targets the U.S. market of 4.5 million annual cataract surgeries, valued at over $3 billion.
LayerBio's CEO Dr. Ken Mandell, a Harvard-trained ophthalmologist and biotechnology entrepreneur, will continue leading the company's operations and product development efforts. The companies plan to advance OcuRing™-K through clinical development in the U.S., with potential expansion into other ophthalmic applications.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
